NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
Clinical Trials
21 trialsNCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04610736 2025-07-31
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Orphelia Pharma
Phase 1 Completed
NCT04724369 2025-03-26
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 3 Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT02998983 2023-09-11
Racotumomab in Patients With High-risk Neuroblastoma
Laboratorio Elea Phoenix S.A.
Phase 2 Completed
NCT03236857 2023-05-22
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
Phase 1 Completed
NCT02982941 2022-02-08
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
Phase 1 Completed
NCT03291080 2021-10-19
My-CRA
Nova Laboratories Limited
Phase 1/2 Completed
NCT02748135 2021-01-13
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Oncurious NV
Phase 1 Completed
NCT01742286 2020-06-09
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Phase 1 Completed
NCT01587703 2020-03-16
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
GlaxoSmithKline
Phase 1 Completed
NCT01222780 2020-01-18
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT00126412 2019-05-31
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
GE Healthcare
Phase 3 Completed
NCT00659984 2017-10-04
N2007-01: Ultratraceā¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Completed
NCT01288573 2017-05-16
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Sanofi
Phase 1/2 Completed
NCT01169584 2016-01-21
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Phase 1 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT01598454 2015-07-29
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Laboratorio Elea Phoenix S.A.
Phase 1 Completed
NCT00520936 2011-02-25
A Study of Pemetrexed in Children With Recurrent Cancer
Eli Lilly and Company
Phase 2 Completed